BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AVZO-023 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AVZO-023\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06998407-9112@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AVZO-023: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:AVZO-023\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With A
 VZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/avzo-023#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06998407
URL:https://assetmemo.bio/drug/avzo-023#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
